LIMNW
Liminatus Pharma, Inc.
Key Financials
Net Income
$-10206517
↓ 187.8%
Operating Income
$-2967812
↑ 10.9%
Total Assets
$512795.00
↓ 90.5%
EPS (Diluted)
$-0.43
↓ 115.0%
Total Liabilities
$10.3M
↓ 58.3%
Shareholders' Equity
$-9814690.00
↑ 49.3%
Operating Cash Flow
$-9963318.00
↓ 586.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 8/18/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| 8-K | 8/4/2026 | View on SEC |
| 8-K | 7/30/2026 | View on SEC |
| 8-K | 7/24/2026 | View on SEC |
| SCHEDULE 13G | 7/22/2026 | View on SEC |
| 4 | 7/14/2026 | View on SEC |
| SCHEDULE 13D/A | 7/14/2026 | View on SEC |
| DEF 14A | 7/13/2026 | View on SEC |
| 4 | 7/6/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | LIMNW |
| Company Name | Liminatus Pharma, Inc. |
| CIK | 1971387 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 213-273-5453 |